PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today affirmed its ongoing collaboration with Takeda Pharmaceutical Company Limited for the global development and commercialization of Hematide™, Affymax’s lead product candidate for the treatment of anemia, continues to progress as planned.
